Repligen (NASDAQ:RGEN) Upgraded to Overweight at Stephens

Repligen (NASDAQ:RGEN - Get Free Report) was upgraded by Stephens to an "overweight" rating in a report issued on Tuesday, MarketBeat reports. The brokerage currently has a $160.00 price objective on the biotechnology company's stock. Stephens' price target points to a potential upside of 31.43% from the company's previous close.

RGEN has been the topic of a number of other research reports. Canaccord Genuity Group dropped their target price on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a report on Wednesday, April 16th. Evercore ISI lowered their price target on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target for the company in a research report on Tuesday, April 29th. JPMorgan Chase & Co. lowered their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Finally, Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $169.92.

Repligen Stock Performance

Shares of RGEN stock opened at $121.74 on Tuesday. Repligen has a 12 month low of $102.96 and a 12 month high of $182.52. The stock has a market cap of $6.84 billion, a PE ratio of -270.53, a price-to-earnings-growth ratio of 2.27 and a beta of 1.11. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27. The company's fifty day moving average price is $123.58 and its 200-day moving average price is $137.45.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The firm had revenue of $169.17 million for the quarter, compared to analysts' expectations of $163.65 million. During the same quarter in the previous year, the business posted $0.28 EPS. The company's quarterly revenue was up 10.4% on a year-over-year basis. On average, equities analysts expect that Repligen will post 1.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Repligen

A number of hedge funds have recently bought and sold shares of the business. Alliance Wealth Advisors LLC UT raised its position in Repligen by 2.5% in the 1st quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company's stock worth $468,000 after buying an additional 89 shares during the last quarter. Utah Retirement Systems raised its position in Repligen by 1.1% in the 4th quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock worth $1,338,000 after buying an additional 100 shares during the last quarter. State of Michigan Retirement System raised its position in Repligen by 0.8% in the 1st quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock worth $1,585,000 after buying an additional 100 shares during the last quarter. Louisiana State Employees Retirement System raised its position in Repligen by 0.7% in the 1st quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company's stock worth $1,858,000 after buying an additional 100 shares during the last quarter. Finally, Peapack Gladstone Financial Corp increased its position in shares of Repligen by 5.2% during the 4th quarter. Peapack Gladstone Financial Corp now owns 2,089 shares of the biotechnology company's stock valued at $301,000 after purchasing an additional 103 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.